This randomised, double-masked Phase I/II trial (n=20) will study the safety, tolerability, and efficacy of psilocybin (10mg vs 30mg) across four sessions for the treatment of obsessive-compulsive disorder (OCD).
Randomised, triple-masked Phase I/II parallel-group trial of 20 symptomatic, medication-free OCD patients assigned to low (10 mg) or high (30 mg) psilocybin across four supervised oral dosing sessions separated by three weeks.
Outcomes include Y-BOCS severity, functioning and quality of life, safety and tolerability measures, subjective experience, and mechanistic measures including fMRI and EEG; follow-up to 12 weeks will assess durability and adverse events.
Low dose psilocybin (10 mg) given across four dosing sessions, 3-week intervals.
10 mg per dosing session; sessions separated by 3 weeks.
High dose psilocybin (30 mg) given across four dosing sessions, 3-week intervals.
30 mg per dosing session; sessions separated by 3 weeks.